Table 2.
Baseline characteristics of patients (post-PSM)
| Characteristics | Negative group | Positive group | P value |
|---|---|---|---|
| No. of cases | 44 | 29 | |
| Sex (male/female) | 41/3 | 25/4 | 0.322 |
| Age (years, <65/≥65) | 42/2 | 28/1 | 0.817 |
| Child-Pugh class (A/B/C) | 41/3/0 | 28/1/0 | 0.536 |
| MELD score (range) | 4.38 (−2.59 to 9.70) | 3.16 (−4.63 to 9.33) | 0.061 |
| Number of tumors (single/multiple) | 30/14 | 20/9 | 0.944 |
| Pathological differentiation (well/moderately/poorly) | 1/20/23 | 0/8/21 | 0.193 |
| Maximum tumor diameter (</≥5 cm) | 5/13/26 | 2/8/19 | 0.777 |
| Tumor capsule (no/incomplete/complete) | 15/16/13 | 7/10/12 | 0.520 |
| MaVI (Y/N) | 4/40 | 2/27 | 0.738 |
| MVI (Y/N) | 27/17 | 18/11 | 0.952 |
| Ascites (Y/N) | 11/33 | 5/24 | 0.433 |
| Cirrhosis (Y/N) | 33/11 | 22/7 | 0.933 |
| White blood cells (×109/L) | 6.35 (2.9–12.8) | 6.50 (3.26–11.55) | 0.757 |
| Platelet count (×109/L) | 195.7 (80–401) | 197.8 (53.7–373.9) | 0.906 |
| Hemoglobin (g/L) | 143 (110–180) | 149 (122–174) | 0.085 |
| Serum ALT (U/L) | 39.2 (13.2–104.0) | 54.4 (18.7–327.2) | 0.187 |
| Serum AST (U/L) | 42.5 (17.2–139.1) | 48.7 (18.5–185.8) | 0.360 |
| Total bilirubin (μmol/L) | 14.2 (4.6–36.6) | 12.2 (6.1–20.2) | 0.119 |
| Albumin (g/L) | 42.3 (29.5–48.2) | 43.9 (32.4–51.0) | 0.074 |
| Prothrombin time (s) | 11.6 (10.1–14.8) | 11.46 (9.7–15.5) | 0.655 |
| Antiviral therapy before(Y/N) | 5/39 | 8/21 | 0.076 |
| HBV DNA (</≥10 000 IU/ml) | 20/24 | 6/23 | 0.031a |
| AFP (ng/ml; ≤400/>400) | 27/17 | 22/7 | 0.197 |
AFP, alpha-fetoprotein; HBV, hepatitis B virus; MaVI, macro vascular invasion; MVI, microvascular invasion.
a
Statistically significant.